Immunocore CEO Bahija Jallal (L) and Gadeta CEO Marcel Zwaal
In search for a 'universal T cell engager', Immunocore inks deal with Gilead-backed Gadeta
Immunocore, which became the first company to win approval for a TCR therapy earlier this year, has penned a deal with gamma delta T cell …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
